Literature DB >> 20877014

Chemotherapy trials in MB leprosy using conventional and newer drugs pefloxacin and minocycline.

K Katoch1, V M Katoch, M Natrajan, V D Sharma, H B Singh, U D Gupta.   

Abstract

One hundred, untreated, smear positive BB, BL and LL patients were treated with a regimen comprising of once a month, supervised, 600 mg of Rifampicin+ 400 mg Ofloxacin + 100 mg of Minocycline in addition to self administered 100 mg dapsone and 50 mg of clofazimine daily for twelve months.The treatment was then stopped and patients were followed up on placebo. This study reports the preliminary results after 2.5 to 3.5 years of post treatment follow-up. The drugs were well tolerated, the clinical response to the treatment was very good, and there was no case of treatment failure. Bacteriologically 25 out of the total 70 patients available for follow- up were still positive at the end of one year of treatment. These patients continued to progress satisfactorily and four patients were still positive at the end of 2 years. No growth was observed in the normal mouse foot pad after one year of therapy. No bacillary ATP was detected in the biopsy tissues after one year. While no M. leprae specific rRNA was detectable in any of the specimens after one year of treatment, weak PCR signals were detectable in 3/57 specimens at that period. In the follow up available no patient has relapsed. The patients are being followed up on placebo and longer follow-up is required to draw firm conclusions.

Entities:  

Year:  2000        PMID: 20877014

Source DB:  PubMed          Journal:  Indian J Dermatol Venereol Leprol        ISSN: 0378-6323            Impact factor:   2.545


  2 in total

1.  Leprosy therapy, past and present: can we hope to eliminate it?

Authors:  P V S Prasad; P K Kaviarasan
Journal:  Indian J Dermatol       Date:  2010-10       Impact factor: 1.494

2.  Fixed-duration therapy in leprosy: limitations and opportunities.

Authors:  Munisamy Malathi; Devinder Mohan Thappa
Journal:  Indian J Dermatol       Date:  2013-03       Impact factor: 1.494

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.